Nature Reviews Immunology (2020) https://doi.org/10.1038/s41577-020-0331-4 Published online 06 May 2020
In the originally published article, the imprecise wording of a sentence implied that IL-6 blockade had been approved by the FDA for treatment of COVID-19. This has now been corrected in the HTML and PDF versions of the article to clarify that the FDA had, at the time of writing, only approved trials of IL-6 blockade in patients with COVID-19.
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
About this article
Cite this article
Merad, M., Martin, J.C. Author Correction: Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages. Nat Rev Immunol 20, 448 (2020). https://doi.org/10.1038/s41577-020-0353-y
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41577-020-0353-y
This article is cited by
-
Label-free macrophage phenotype classification using machine learning methods
Scientific Reports (2023)
-
In vivo inhibition of nuclear ACE2 translocation protects against SARS-CoV-2 replication and lung damage through epigenetic imprinting
Nature Communications (2023)
-
Severe COVID-19 patients exhibit elevated levels of autoantibodies targeting cardiolipin and platelet glycoprotein with age: a systems biology approach
npj Aging (2023)
-
Transcriptional differences between coronavirus disease 2019 and bacterial sepsis
Virology Journal (2022)
-
Different aspects of frailty and COVID-19: points to consider in the current pandemic and future ones
BMC Geriatrics (2021)
